Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $56.00 Consensus Price Target from Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has earned a consensus rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the […]
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has earned a consensus rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the […]
